Pharmacologic treatments for covid-19 patients
Methods
Protocol amendment:
As of March 1, 2022, the COVID-NMA revised its protocol to include only studies evaluating immunomodulators and antiviral therapies. Comparisons evaluating antivirals and immunomodulators will continue to be updated every two weeks.
For treatments that are neither immunomodulators nor antivirals, we provide the updated results up to Feb 28, 2022 including all identified reports through our search strategy up tp this date.
meta-COVID
Perform your own analysis using COVID-NMA data, create and download your forest plots by clicking below:
Treatment comparisons
Create and download your forest plots with the most up-to-date data here Forest plots
Access the forest plots for the 1 treatment comparisons .
Anti-virals (1 comparisons)
Search studies
General characteristics of primary studies
| Trial | Funding | Comparisons | Design | Participants | Sample size | Overall risk of bias Highest assessment |
Full description | |
|---|---|---|---|---|---|---|---|---|
| Treatment 1 | Treatment 2 | |||||||
| NCT04960202 EPIC-HR Hammond J, N Engl J Med, 2022 Full text Commentary |
Private |
Nirmatrelvir/r |
Placebo |
RCT | Outpatients with confirmed COVID-19 (mild) treated by 343 centers in 21 countries | N=2246 |
Some concerns Details |
|